Alkermes plc (NASDAQ:ALKS – Get Rating) COO Blair Curtis Jackson sold 49,999 shares of the firm’s stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $29.61, for a total transaction of $1,480,470.39. Following the completion of the sale, the chief operating officer now owns 87,915 shares in the company, valued at $2,603,163.15. The sale was disclosed in a document filed with the SEC, which is available at this link.
Alkermes stock traded down $1.06 during midday trading on Friday, hitting $28.20. 1,702,973 shares of the company’s stock were exchanged, compared to its average volume of 1,367,104. The stock has a market cap of $4.61 billion, a price-to-earnings ratio of -95.33 and a beta of 0.90. The firm’s 50 day simple moving average is $26.31 and its 200 day simple moving average is $25.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.93 and a current ratio of 2.25. Alkermes plc has a 12-month low of $20.76 and a 12-month high of $33.00.
Alkermes (NASDAQ:ALKS – Get Rating) last issued its earnings results on Wednesday, February 16th. The company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.16. The business had revenue of $324.50 million for the quarter, compared to the consensus estimate of $306.55 million. Alkermes had a negative net margin of 4.10% and a positive return on equity of 3.95%. The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. On average, equities research analysts forecast that Alkermes plc will post -0.6 EPS for the current fiscal year.
A number of research analysts recently commented on the stock. TheStreet raised shares of Alkermes from a “d+” rating to a “c” rating in a research report on Tuesday, March 1st. The Goldman Sachs Group assumed coverage on shares of Alkermes in a research report on Wednesday. They issued a “buy” rating and a $35.00 target price on the stock. SVB Leerink increased their target price on shares of Alkermes from $24.00 to $25.00 and gave the company a “market perform” rating in a research report on Thursday. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 13th. Finally, Citigroup increased their target price on shares of Alkermes from $22.00 to $26.00 and gave the company a “neutral” rating in a research report on Tuesday, March 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, three have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $30.30.
Alkermes Company Profile (Get Rating)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.